Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Programmed death-ligand 1 (PD-L1) expression may vary in different disease sites and at different time points of the disease course. We aimed to investigate PD-L1 heterogeneity and its usefulness as a predictive value for immune checkpoint inhibitor (ICI) therapy in patients with NSCLC. PD-L1 expres...

Full description

Bibliographic Details

Published in:	Journal of thoracic oncology 2020-09, Vol.15 (9), p.1449-1459
Main Authors:	Hong, Lingzhi, Negrao, Marcelo V., Dibaj, Seyedeh S., Chen, Runzhe, Reuben, Alexandre, Bohac, Jadi M., Liu, Xiaoke, Skoulidis, Ferdinandos, Gay, Carl M., Cascone, Tina, Mitchell, Kyle G., Tran, Hai T., Le, Xiuning, Byers, Lauren A., Sepesi, Boris, Altan, Mehmet, Elamin, Yasir Y., Fossella, Frank V., Kurie, Jonathan M., Lu, Charles, Mott, Frank E., Tsao, Anne S., Rinsurongkawong, Waree, Lewis, Jeff, Gibbons, Don L., Glisson, Bonnie S., Blumenschein, George R., Roarty, Emily B., Futreal, P. Andrew, Wistuba, Ignacio I., Roth, Jack A., Swisher, Stephen G., Papadimitrakopoulou, Vassiliki A., Heymach, John V., Lee, J. Jack, Simon, George R., Zhang, Jianjun
Format:	Article
Language:	eng
Subjects:	B7-H1 Antigen - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Heterogeneity Humans Immune checkpoint inhibitor therapy Immune Checkpoint Inhibitors Lung Neoplasms - drug therapy Metastatic non–small cell lung cancer PD-L1 Progression-Free Survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!